Folgen
-
In this last episode of the series, Professor Jacob Thyssen discuss with Professor Tiago Torres, how the new approvals have changed the treatment landscape for atopic dermatitis and how to integrate these new options in the clinical practice. Join them to gain insight in how to identify the most suitable treatment for different patients depending on their specific circumstances, including the presence of comorbidities and how to advance towards a more personalised medicine. You’ll learn about the challenges present in the treatment landscape today and some ways to overcome these barriers.
-
In this episode Professor Jacob Thyssen is joined by Professor Andreas Wollenberg to discuss new and emerging treatment options for atopic dermatitis including the recent approval of the monoclonal antibody tralokinumab in Europe and the United States. They describe clinical data from Phase 2 clinical trials, discuss safety profiles, and highlight the importance of tailoring treatment for the patient in the face of the evolving treatment landscape. In addition, the professors discuss the pathophysiology of atopic dermatitis including the possible relevance of cytokines in disease management.
-
Fehlende Folgen?
-
Listen in on this short and engaging podcast to hear Professor Jacob Thyssen and Professor Jonathan Silverberg discuss recent approval indications of JAK inhibitors in Europe and the US to treat atopic dermatitis. In this session they cover the mode of action, safety and efficacy of JAK inhibitors, including clinical trial evidence, the differences in the adverse events between JAK inhibitor treatment options and a comparison between JAK inhibitors and other commonly prescribed systemic therapies.
